Eli Lilly & Co. Expands Clinical Collaboration with Shanghai East Hospital in China
Eli Lilly & Co. (NYSE: LLY), a leading global pharmaceutical company, has announced an expansion...
Everest Medicines Commences Commercial Sales of Nefecon in China Post-Launch
Everest Medicines (HKG: 1952), a leading pharmaceutical company based in China, has announced the official...
Elite (Suzhou) Analytical Instruments Boosts Liquid Chromatography Push with Series A+ Round
China-based Elite (Suzhou) Analytical Instruments Co., Ltd, a premier manufacturer of liquid chromatography devices in...
US Readies Hefty Tariffs on Chinese Medical Equipment and Other Imports
The US Office of the Trade Representative (USTR) has announced a series of stringent new...
Genmab CEO Cites China’s Biotech as a ‘Mind-Boggling’ Source of Innovation
Jan van de Winkel, CEO of Denmark-based biotech Genmab (NASDAQ: GMAB), has expressed optimism about...
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Zai Lab Advances Vygart Hytrulo for CIDP with sBLA Filing in China
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, has announced...
Jiangsu Hengrui’s SHR-2173 Gets Green Light for Clinical Trial in IgA Nephropathy
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...
China Launches Nationwide Unannounced Inspections of Medical Insurance Funds
An inaugural meeting for the first batch of unannounced medical insurance fund inspections was conducted...
Novo Nordisk’s Wegovy Shows Durable Weight Loss and Heart Health in Extended Trials
At the 31st European Congress on Obesity (ECO), Denmark’s pharmaceutical giant Novo Nordisk (CPH: NOVO-B)...
RemeGen’s Telitacicept Achieves Full Enrollment in Phase III Primary Sjogren’s Syndrome Trial
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the completion of patient enrollment in a...
Bayer’s Q1 2024 Report Shows Slight Dip in Sales Amid Pharmaceutical Unit’s Growth
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2024,...
Novo Nordisk’s Bispecific Antibody Mim8 Achieves Milestone in Haemophilia A Trial
Novo Nordisk (CPH: NOVO-B), a pharmaceutical company based in Denmark, has announced that its bispecific...
Novo Nordisk’s Mim8 for Haemophilia A Exceeds Endpoints in Late-Stage Trial
Denmark-based healthcare company Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Roche and Genprex Initiate Phase I Trial Combining Tecentriq and Reqorsa for ES-SCLC
Switzerland-based Roche (SWX: ROG) is advancing the evaluation of its anti-PD-L1 drug, Tecentriq (atezolizumab), in...
BeiGene’s Brukinsa Secures Conditional Approval in China for R/R Follicular Lymphoma
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China,...
AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies
AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio...
MSD Discontinues Vibostolimab and Keytruda Combo Trial in High-Risk Melanoma
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of...